Is hybridoma production about to take a quantum leap forward?

Two cultures derived from the same culture of a stable hybridoma clone were grown, one in NPD and the other in DI based medium supplemented with 3 percent FCS. Before... Click here for more information.

Recently published research* has established the ability of Neowater® to enhance the various processes involved in the production of pure human monoclonal antibodies by refining the standard hybridoma production process.

Biopharmaceutical companies have started to evaluate the use of fully human monoclonal antibodies as a complementary or primary therapeutic agent against a variety of diseases. The most obvious advantage would be to bypass the interference from the patient's immune system that typically characterizes the use of chemerical or humanized antibodies. Due to the growing interest and the potential benefits, the efficient production of human monoclonal antibodies is a high priority. But any attempt to produce these by natural means encounters formidable obstacles, not only from an ethical standpoint but also from the difficulty inherent in generating human antibodies against human tissues.

The capacity to humanize monoclonal antibodies in 1988 through hybridoma cell production methods opened exciting new vistas in R&D and biomed products. If this method could be further refined to produce pure, natural human monoclonal antibodies, research would take a quantum leap forward in the development of new medical and pharmaceutical discoveries for serious and life-threatening conditions that cannot yet be successfully treated with synthesized hybrids.

One proven way to profoundly enhance the media solutions used for cell growth, and particularly membrane proteins, is Radio Frequency (RF) radiation. The RF is absorbed by the aqueous solution and stimulates new membrane formation - a vital stage in hybridoma cell growth. The problem is that the beneficial effect decays once the source of RF is removed, and the new membrane formation does not receive the full benefit. Without this extra "boost", the delicate process of producing viable, fully human monoclonal antibodies faces an insurmountable obstacle.